10-Q: BioRegenx Faces Going Concern Amid Revenue Decline

BioRegenx, Inc. reports a reduced net loss but faces significant revenue decline and ongoing going concern doubts, with key loans in default and material weaknesses in internal controls.

Summary

• Net loss for the six months ended June 30, 2025, significantly improved to $445,199 from $4,258,586 in the prior year period.
• Net sales decreased by 25% to $961,116 for the six months ended June 30, 2025, compared to $1,283,580 in the same period of 2024, primarily due to product issues with the medical testing machine.
• Gross profit declined by 11% to $758,486 for the six months ended June 30, 2025, from $854,036 in the prior year.
• Cash and cash equivalents stood at $46,456 as of June 30, 2025, a decrease from $58,404 at December 31, 2024.
• Total liabilities increased to $4,805,266 as of June 30, 2025, from $3,887,794 at December 31, 2024.
• Stockholders' deficit widened to $3,654,708 as of June 30, 2025, from $3,379,259 at December 31, 2024.
• Notes payable and loans totaling $522,500 are currently in default.
• The company entered into a new sub-license and purchase agreement for GlycoCheck systems on May 5, 2025, with a minimum royalty commitment of $750,000 over three years and a $1,000,000 purchase option payable in common shares.
• Cash provided by operating activities was $40,900 for the six months ended June 30, 2025, a significant improvement from $281,591 cash used in operating activities in the prior year period.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, including recurring losses, a widening stockholders' deficit, and significant debt in default. While the net loss decreased and cash from operations improved, the substantial decline in sales due to product issues, coupled with explicit 'going concern' doubts and critical internal control weaknesses, indicates a highly precarious situation. The legal disputes and reliance on future financing without a clear solution further compound the negative outlook.

Positives

• Net loss significantly reduced to $445,199 for the six months ended June 30, 2025, from $4,258,586 in the comparable prior year period, representing an 89.5% improvement.
• Cash flow from operating activities turned positive, providing $40,900 for the six months ended June 30, 2025, compared to using $281,591 in the same period of 2024, attributed to management's efforts to reduce expenses and conserve cash.
• Selling, general and administrative expenses decreased by 78% for the six months ended June 30, 2025, primarily due to reduced equity compensation and amortization costs.

Negatives

• Net sales decreased by 25% for the six months ended June 30, 2025, primarily due to product issues experienced with the medical testing machine and its effect on nutritional sales.
• Gross profit decreased by 11% for the six months ended June 30, 2025, reflecting lower product sales.
• The company has generated recurring losses and cash flow deficits since inception, raising substantial doubt about its ability to continue as a going concern.
• Notes payable totaling $522,500 are in default as of June 30, 2025.
• Cash and cash equivalents declined to $46,456 as of June 30, 2025, from $58,404 at December 31, 2024.
• Total liabilities increased to $4,805,266 as of June 30, 2025, from $3,887,794 at December 31, 2024.
• Stockholders' deficit worsened to $3,654,708 as of June 30, 2025, from $3,379,259 at December 31, 2024.
• The company has material weaknesses in internal control over financial reporting, including an ineffective control environment, insufficient personnel, inadequate segregation of duties, and lack of written documentation.

Risks

• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses and cash flow deficits.
• Dependence on obtaining necessary debt or equity financing to continue operations, with no assurance of availability or satisfactory terms.
• Future financing may contain undue restrictions on operations (debt) or cause substantial dilution for stockholders (equity).
• Notes payable of $522,500 are in default, which could lead to accelerated payments or other adverse actions by lenders.
• Ongoing legal dispute with former officers and directors of GlycoCheck B.V. claiming damages in excess of $566,682 for alleged breach of contract and unpaid royalties.
• Dispute with a VHS Pool member regarding a potential liquidity event that could accelerate royalty payments.
• Other undisclosed disputes with former officers, board members, and vendors, which could result in material adverse effects.
• Ineffective control environment due to lack of a functioning independent audit committee, insufficient board review of significant transactions, and inadequate qualified personnel.
• Material weaknesses in internal control over financial reporting, including insufficient preparation and review procedures for financial statement disclosures and lack of proper account reconciliations.
• Insufficient segregation of duties in finance and accounting functions due to limited personnel, increasing the risk of undetected errors.

Future Outlook

Management anticipates generating losses and may be unable to continue operations in the future without additional capital. The company requires additional capital to develop its business and may seek a combination of equity and/or debt instruments or strategic arrangements, but has not yet found a solution to its funding requirements.

Management Comments

• Management has concluded that there is substantial doubt about the company's ability to continue as a going concern.
• The improvement in cash from operations related to efforts of management to reduce expenses and conserving cash by managing aging schedules and using equity compensation.
• The company anticipates generating losses and therefore may be unable to continue operations in the future.
• Management has yet to find a solution to its funding requirements.

Industry Context

The company operates in the medical test equipment, wellness devices, and nutritional products sectors. The reported decline in net sales due to 'product issues experienced with the medical testing machine' suggests a significant challenge in a competitive market that demands high product reliability and efficacy. The focus on acquiring non-invasive medical and wellness devices and developing related AI and bioinformatics aligns with broader industry trends towards digital health and personalized wellness, but the company's current financial and operational challenges hinder its ability to capitalize on these trends.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• Lawsuit filed by former officers and directors of GlycoCheck B.V. on April 21, 2025, alleging breach of contract and unjust enrichment, claiming damages exceeding $566,682. The company considers these claims without merit.
• Dispute with a VHS Pool member regarding a potential liquidity event that could accelerate royalty payments, with a tolling agreement in place until June 30, 2026.
• Involvement in other undisclosed disputes with certain parties, including former officers, board members, and vendors, arising in the ordinary course of business.

Related Party Transactions

• Rental of office space from BBD Holdings, LLC, controlled by Joseph Bird (officer and director), at $1,725 per month.
• Royalties paid to the VHS Pool, in which Robert Long (former officer and director) has a creditor interest.
• Distribution agreement with GlycoCheck B.V., whose former directors (Bob Long and Hans Vink) were also former officers and directors of BioRegenx.
• Legal services provided by Jody Walker (former board member) through her firm, with $72,061 owed as of June 30, 2025.
• Short-term advances from Resides Enterprises (controlled by William Resides, CEO) totaling $253,921 and from Thomas Power totaling $51,250 as of June 30, 2025.
• Balances due to prior officers and board members totaling $27,202 as of June 30, 2025.
• Unsecured borrowings from related parties: Libertas Trust ($180,000), Wilshire Holding Trust ($518,000), Resco Enterprises Trust ($157,747), Avis Trust ($67,606), JS Bird ($32,079), Thomas Power ($32,591), and Richard Long ($39,862).
• Certain related party loans are secured by all assets of the company or its subsidiaries, as evidenced by UCC Financing Statements.

Stakeholder Impact

• Shareholders face significant dilution risk from potential future equity financing and the $1,000,000 purchase option for GlycoCheck payable in common shares.
• Shareholders are exposed to substantial risk due to the company's 'going concern' doubts, recurring losses, and notes in default, which could lead to a loss of investment.
• Creditors (including related parties) face repayment risk given the company's financial instability and defaulted loans.
• Employees and contractors may face uncertainty regarding job security and compensation due to the company's financial challenges and reliance on equity compensation.
• Customers may experience continued product issues and potential disruptions in service or product availability, as indicated by past delivery delays and product issues with the medical testing machine.
• Suppliers may face payment delays or non-payment given the company's cash flow deficits and accounts payable balances.

Next Steps

• Management intends to raise additional debt or equity financing to fund ongoing operations and working capital.
• Remediation efforts for identified material weaknesses in internal control over financial reporting are ongoing.
• The company is obligated to exercise a purchase option for the GlycoCheck intangible property for $1,000,000, payable in common shares, within the three-year sub-license term.
• The company and a VHS Pool Member are negotiating terms of a revised royalty agreement, with a tolling of the statute of limitations until June 30, 2026, or 60 days after termination of the agreement.

Key Dates

Recommendation

The company explicitly states 'substantial doubt about its ability to continue as a going concern,' which is a critical red flag for any investor. Despite a reduction in net loss, the significant decline in net sales due to product issues, coupled with a widening stockholders' deficit and a substantial amount of debt in default, indicates severe financial distress. The identified material weaknesses in internal controls and ongoing legal disputes further undermine confidence in management and future prospects. The reliance on uncertain future financing, with potential for significant shareholder dilution, makes this a high-risk investment with a strong likelihood of further value erosion.

Keywords

Medical Devices, Nutraceuticals, Wellness Devices, Biotherapeutics, Anti-aging, Healthcare Technology, SEC Filing, Quarterly Report, Going Concern, Financial Performance, Corporate Governance, Risk Management